Letybo (Botulinum Toxin Type A)

Botulinum toxin type A cleaves the SNAP‑25 protein, a key component of the SNARE complex that mediates acetylcholine release at the neuromuscular junction. By disrupting this fusion process, the toxin blocks acetylcholine transmission, leading to a reversible reduction in muscle contraction at the injection site.

The dose of Letybo is individualized by the prescribing clinician based on the specific indication, severity of the condition, muscle mass, and patient response. Dosing regimens are not standardized in public literature; therefore, the prescriber determines the appropriate amount and injection pattern for each patient.

Safety data for Letybo in pregnancy and lactation are limited. Use is generally avoided unless the potential therapeutic benefit justifies the potential risk to the fetus. Likewise, breastfeeding mothers should weigh the benefits against possible drug exposure to the infant, as excretion in milk has not been fully characterized.

To request Letybo, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and any required import documentation.

Letybo is a botulinum toxin type A formulation similar in mechanism to other branded type‑A products such as onabotulinumtoxinA and incobotulinumtoxinA. Differences may exist in manufacturing process, unit potency, excipients, and approved indications. Clinicians choose a product based on clinical experience, regulatory approvals in their region, and specific patient needs.

Letybo should be stored in a refrigerator at 2 °C to 8 °C. The vial must be kept in its original packaging, protected from light, and must not be frozen or shaken. Maintaining the cold chain preserves the biological activity of the toxin until the point of use.

Letybo is supplied as a sterile injectable solution for intramuscular injection. A qualified healthcare professional reconstitutes the vial with the appropriate diluent, draws the calculated dose into a syringe, and injects it directly into the targeted muscle or skin area using standard aseptic technique.

Serious adverse events include dysphagia (difficulty swallowing), respiratory compromise, a botulism‑like syndrome with generalized muscle weakness, and severe allergic reactions such as anaphylaxis. These risks are related to toxin spread beyond the injection site and require immediate medical attention if they occur.

Letybo is contraindicated in individuals with a known hypersensitivity to botulinum toxin type A or any of its excipients, including human serum albumin. Patients with neuromuscular junction disorders such as myasthenia gravis or Lambert‑Eaton syndrome should avoid treatment unless a specialist determines it is safe. Pregnant or breastfeeding women should only use it when the benefits clearly outweigh the risks.